A comprehensive view of New Drug / Biologic License Application (NDA / BLA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
Published: May 17, 2024 by BioNTech SE
Australia Patent: AstraZeneca Files Application for 'METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES'
Published: May 17, 2024 by Australian Government
Researchers Submit Patent Application, 'Compound For The Treatment Of Cancer', for Approval (USPTO 20240140947)
Published: May 17, 2024 by NewsRx Women’s Health Daily
Patent Issued for Tricyclic AKR1C3 dependent KARS inhibitors (USPTO 11970497)
Published: May 16, 2024 by NewsRx Pharma Business Daily
Eisai initiates rolling submission of BLA to FDA for Leqembi subcutaneous autoinjector; Leqembi already approved for early Alzheimer's disease treatment in the US, China, and Japan.
Published: May 15, 2024 by Zack's Commentary

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count